03月 26日, 2019
新旭生技獲《數位時代》媒體與科技部合作2019年度台灣「最酷科技新創」評選。從122家符合資格的科技新創公司中，脫穎而出位列前十。
經編輯團隊研究、整理相關基本資料後，共有 122 家新創團隊符合前述資格，由《數位時代》所邀請領域專家就技術能量、國際市場發展潛力、產業影響力與團隊發展潛能等四面向進行線上評分，以序分法評選出領域專家共同認定最具潛力的20家新創企業，再經由專家諮詢會議討論，評選出｢2019年台灣最創新的10家科技類新創」。
以下是數位時代報導全文：
12月 25日, 2018
APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases, announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [ F]-labeled positron emission tomography (PET) imaging tracer, to suppo...
09月 01日, 2018
APRINOIA Will Participate Asia-China: 2018 Clinical Trials on Alzheimer’s Disease Conference
APRINOIA will sponsor the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.
01月 16日, 2018
APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (T...
12月 15日, 2017
APRNIOIA Will participate 2018 Human Amyloid Imaging Conference
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.
12月 15日, 2017
APRNIOIA Will Participate 2018 AAT-AD/PD Focus Meeting
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.
12月 15日, 2017
APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation
APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.
12月 12日, 2016
APRINOIA Will Present its 1st Clinical Trial Results at 2017 Human Amyloid Imaging Conference
APRINOIA will present the first-in-the-human clinical trial results for its Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.
